Notice of Intent to Award Multiple Blanket Purchase Agreements for Sterilely Compounded Pharmaceuticals via 503B Compounding Pharmacies for Gallup Indian Medical Center

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAVAJO AREA INDIAN HEALTH SVC

Contract Value

Not provided

Codes & Classification
Solicitation Number

NOI-GSUT2-20260003

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Gallup, New Mexico, UNITED STATES

SourceSAM
The Navajo Area Indian Health Service (IHS), specifically the Gallup Service Unit located in Gallup, New Mexico, has issued a Special Notice indicating its intent to establish multiple Blanket Purchase Agreements (BPAs) for the provision of sterilely compounded pharmaceuticals. This procurement activity is designed to support the ongoing pharmaceutical needs of the Gallup Indian Medical Center by securing reliable access to critical medications that must be compounded in accordance with FDA regulations. The scope of this initiative encompasses the acquisition of various sterilely compounded drugs from FDA-designated 503B compounding facilities. The medications specified include Phenylephrine 100mcg/ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytocin 30 units in 500ml (both sterile-to-sterile and active pharmaceutical ingredient [API] forms), and Epinephrine 8mg per 250ml bag, as well as other strengths and volumes of these medications in IV bags as required. All products must be compounded in FDA-approved facilities and possess a beyond-use date of at least 30 days from the date of manufacture, ensuring both safety and efficacy for patient care. The intended outcome of this procurement is to establish multiple-award BPAs with Fagron Compounding Services LLC (UEI: F7QNV46N18Q4) and American National Services LLC (UEI: LDNAY53JNV24), enabling the Gallup Indian Medical Center to order these pharmaceuticals on an as-needed basis. The agreements will feature a base period of one year from the date of award, with the possibility of a one-year option period, providing flexibility and continuity in supply. This procurement is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with a small business size standard of 1,300 employees. The Product Service Code (PSC) is 6505, which pertains to drugs and biologicals. The place of performance is Gallup, New Mexico, United States. The notice emphasizes that no further awards are anticipated unless the needs of the Gallup Indian Medical Center change. The establishment of these BPAs is considered to represent maximum practicable competition in accordance with FAR Part 12.201-1(e)(3)(i)(A). However, the government encourages other capable sources to submit capability statements, price lists, and catalogs via email to the designated point of contact, Rodney Brown ([email protected]), by 10:00 AM (MST) on February 18, 2026. Should additional BPAs be deemed beneficial, the government may reach out to qualified vendors for potential agreement establishment. It is important to note that this notice is not a request for quotations, and no formal solicitation will be issued. Interested parties should respond only if they can meet the outlined requirements and are prepared to provide the specified sterilely compounded pharmaceuticals from FDA-approved 503B facilities. For contractors considering this opportunity, the key requirements are the ability to supply sterilely compounded pharmaceuticals with a minimum 30-day beyond-use date, compliance with FDA 503B facility standards, and readiness to fulfill orders on an as-needed basis for the Gallup Indian Medical Center. The procurement is managed by the Navajo Area Indian Health Service, a federal entity under the Department of Health and Human Services, Indian Health Service. Further details and updates can be accessed via the official notice on SAM.gov (Opportunity ID: 15ca861659c349c1813230c20c2a8d79).